Erving Goffman

Evaxion announces financing commitments totaling up to USD 20 million with Negma Group

Retrieved on: 
Tuesday, August 1, 2023
Lung cancer, Cancer, USD, Erving Goffman, ASCO, Equity capital markets, VWAP, Patient, Growth, Pharmaceutical industry

At Negma Group, we invest in people who bring forth forward-thinking, data-driven solutions.

Key Points: 
  • At Negma Group, we invest in people who bring forth forward-thinking, data-driven solutions.
  • We are proud to partner with Evaxion as they advance the next-generation personalized cancer vaccines to develop superior immunotherapies for patients in need,” said Sophie Villedieu, Equity Capital Market of Negma Group.
  • “We are pleased to be able to establish a flexible financing vehicle with Negma Group.
  • If Evaxion fully utilizes the convertible note program, the company will have sufficient financing to fund its planned activities into Q4 2024.

Evaxion Announces Business Update and First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 31, 2023
Vaccine, Exercise, DNA, AACR, European Medicines Agency, Survival, Infection, Cancer, CTA, CCL19, Immunotherapy, Messenger, Observational study, Erving Goffman, ASCO, Research and development, Development, Patient, Administration, Melanoma, Koala retrovirus, Research, Safety, Genome, Medical imaging, Pharmaceutical industry

“Evaxion continues to make significant progress towards our mission of advancing AI-powered immunotherapies to save lives,” said Per Norlén, Chief Executive Officer of Evaxion.

Key Points: 
  • “Evaxion continues to make significant progress towards our mission of advancing AI-powered immunotherapies to save lives,” said Per Norlén, Chief Executive Officer of Evaxion.
  • Operating spending for the first quarter of 2023 was offset by the proceeds from issue of shares and exercise of warrants.
  • Research and Development expenses were $3.9 million for the quarter ended March 31, 2023 as compared to $4.8 million for the quarter ended March 31, 2022.
  • General and Administrative expenses were $2.5 million for the quarter ended March 31, 2023 as compared to $1.6 million for the quarter ended March 31, 2022.

Fourth quarter and full year 2022 financial results and business update

Retrieved on: 
Thursday, April 27, 2023
Antigen, Commercialization, AACR, ExpreS2ion Biotechnologies, University of Massachusetts, CPI, S. aureus, Neoplasm, Novel, European Medicines Agency, Aes, Cancer, CTA, Immunotherapy, EDT, Messenger, Sepsis, Erving Goffman, ASCO, Research and development, Development, American Society of Clinical Oncology, Patient, Administration, Data, Melanoma, CMV, Annual general meeting, Toxicology, Webcast, Koala retrovirus, PD-1, Research, Recurrence, IND, Society, NIH, Nivolumab, Pharmaceutical industry, Medical device, Cryptocurrency, Perfume, Vaccine

Technology advances: Novel ObsERV™ technology -- In March 2023, Evaxion reported the discovery of a novel new source of antigens for personalized cancer immunotherapy, based on endogenous retroviruses (ERVs). The AI-enabled technology has the potential to make “cold” tumors responsive to immunotherapy, which has the potential to broaden the patient population for immunotherapy significantly.

Key Points: 
  • Looking ahead to the rest of the year, we plan to report final Phase 1/2a results and interim Phase 2 data from the EVX-01 program in melanoma.
  • In addition, we intend to initiate recruitment in a Phase 1 study with EVX-03 in Q4 2023.
  • The Phase 2 study, initiated in September 2022, is expected to enroll up to 20 patients and report interim data in Q4 2023.
  • EVX-B2 (N. gonorrhoeae, preclinical) – In June 2022, Evaxion announced gonorrhea as a new bacterial vaccine candidate for N. gonorrhoeae.

Satellite Healthcare Named to Parity.org Best Companies for Women to Advance List for Two Consecutive Years

Retrieved on: 
Wednesday, July 7, 2021
Research, Medical devices, Human resources, Diabetes, Clinical trials, Professional services, Managed care, Health, Science, Other Science, Canadian writers, Erving Goffman, Symbolic interactionism, Sociologists, Parity.org, the Best Companies for Women to Advance List, Satellite Healthcare, PARITY.ORG, THE BEST COMPANIES FOR WOMEN TO ADVANCE LIST, SATELLITE HEALTHCARE

Satellite Healthcare, a not-for-profit kidney care company, has been named to the Parity.org Best Companies for Women to Advance List 2021.

Key Points: 
  • Satellite Healthcare, a not-for-profit kidney care company, has been named to the Parity.org Best Companies for Women to Advance List 2021.
  • Jeff Goffman, Satellite Healthcare CEO, expressed, Its an honor to be included on the Parity.org list for the second consecutive year.
  • The companies that are on the 2021 list of Best Companies for Women to Advance are shining examples of companies that actually walk the talk and are helping create equal representation, now.
  • Parity.org established the Best Companies for Women to Advance List to recognize organizations that have benefits, policies, and programs that are particularly beneficial for women to advance in the workplace.

Satellite Healthcare Names Industry Veteran Jeffrey Goffman as CEO

Erving Goffman, Symbolic interactionism, GE Healthcare, Canadian writers

SAN JOSE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Satellite Healthcare, the leading nonprofit dialysis provider, today announced Jeffrey Goffman will be its next CEO, effective January 2, 2021.

Key Points: 
  • SAN JOSE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Satellite Healthcare, the leading nonprofit dialysis provider, today announced Jeffrey Goffman will be its next CEO, effective January 2, 2021.
  • Goffman brings nearly 30 years of health care industry leadership to Satellite, with expertise in physician practice management, large healthcare system joint ventures, ancillary services and value-based care models.
  • We are pleased to welcome Jeffrey Goffman as our next CEO, an industry veteran who understands the importance of expanding access to critical care services like dialysis, said Christobel Selecky, chair of the Satellite Healthcare Board of Directors.
  • Prior to Satellite, Goffman served as CEO of Integrated Oncology Network for more than a decade.

Jay M. Goffman To Receive The 2020 M&A Advisor Lifetime Achievement Award

Retrieved on: 
Tuesday, February 25, 2020
Businesspeople, Economy of the United States, Science and technology in the United States, Guggenheim Fellows, Erving Goffman, Symbolic interactionism, Paul Allen

NEW YORK, Feb. 25, 2020 /PRNewswire/ --The M&A Advisor is proud to announce that Jay M. Goffman is the recipient of the 2020 M&A Advisor Lifetime Achievement Award.

Key Points: 
  • NEW YORK, Feb. 25, 2020 /PRNewswire/ --The M&A Advisor is proud to announce that Jay M. Goffman is the recipient of the 2020 M&A Advisor Lifetime Achievement Award.
  • Mr. Goffman also played a leading role in Charter Communications' prearranged restructuring, representing Paul Allen as the owner.
  • "We are excited to present Jay M. Goffman with the 2020 M&A Advisor Lifetime Achievement Award," said Roger Aguinaldo, Founder of The M&A Advisor.
  • The M&A Advisor was founded in 1998 to offer insights and intelligence on mergers and acquisitions through the industry's leadingpublication.